Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multicenter, Open-label, Single-arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate Atopic Dermatitis and High Itch Burden

NCT07006792 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07006792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07006792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multicenter, Open-label, Single-arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate Atopic Dermatitis and High Itch Burden
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Active, not recruiting
Start date
June 16, 2025
Completion date
September 30, 2026
Enrollment
233 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis